A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer

Published:2021-02 Issue:1 Volume:19 Page:22-31.e5
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Spetsieris Nicholas,Boukovala Myrto,Weldon Justin A.,Tsikkinis Alexandros,Hoang Anh,Aparicio Ana,Tu Shi-Ming,Araujo John C.,Zurita Amado J.,Corn Paul G.,Pagliaro Lance,Kim Jeri,Wang Jennifer,Subudhi Sumit K.,Tannir Nizar M.,Logothetis Christopher J.,Troncoso Patricia,Wang Xuemei,Wen Sijin,Efstathiou Eleni

Funder

National Institutes of Health

Prostate Cancer Foundation

Janssen Pharmaceuticals

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference40 articles.

1. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study;Beer;Eur Urol,2017

2. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study;Ryan;Lancet Oncol,2015